IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1355-1365

  Fukuda, Masakatsu ^a   Ehara, Masahiro ^a   Suzuki, Seiji ^a   Ohmori, Yoshihiro ^a   Sakashita, Hideaki ^a  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Human oral squamous cell carcinomas; Interleukin (IL) 23; Nuclear factor kappaB (NF B); p65 rela; PAb IL 23p19; TNF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER LOCALIZATION; CELL GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-23; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 77951618566     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000620     Document Type: Article

References (39)

1. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
2. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
3. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M: IL-23 promotes tumour incidence and growth. Nature 27: 461-465, 2006. (Pubitemid 44264796)
4. Oppmann B, Lesley R, Blom B, et al: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725, 2000.
5. Sospedra M and Martin R: Immunology of multiple sclerosis. Annu Rev Immunol 23: 683-747, 2005.
6. Parham C, Chirica M, Timans J, et al: A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708, 2002. (Pubitemid 34556153)
7. Lankford CSR and Frucht DM: A unique role for IL-23 in promoting cellular immunity. J Leukocyte Biol 73: 49-56, 2003.
8. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993. (Pubitemid 23277355)
9. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-production. J Immunol 153: 1697-1706, 1994.
10. Cua DJ, Sherlock J, Chen Y, et al: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748, 2003. (Pubitemid 36227625)
11. Murphy CA, Langrish CL, Chen Y, et al: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint auto-immune inflammation. J Exp Med 198: 1951-1957, 2003.
12. Becher B, Durell BG and Noelle RJ: IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 112: 1186-1191, 2003. (Pubitemid 38056295)
13. Piskin G, Sylva-Steenland RMR, Bos JD and Teunissen MBM: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176: 1908-1915, 2006.
14. Fukuda M, Ehara M, Suzuki S and Sakashita H: Expression of interleukin-23 and its receptors in human squamous cell carcinoma of the oral cavity. Mol Med Rep 3: 89-93, 2010.
15. Karin M: How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 18: 6867-6874, 1999.
16. Li Q and Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734, 2002.
17. Karin M, Cao Y, Greten FR and Li ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2: 301-310, 2002. (Pubitemid 37328783)
18. Orlowski RZ and Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8: 385-389, 2002.
19. Baeuerle PA and Baltimore D: I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546, 1988. (Pubitemid 18263193)
20. Rodriguez MS, Thompson J, Hay RT and Dargemont C: Nuclear retention of IκBα protects it from signal-induced degradation and inhibits nuclear factor κB transcriptional activation. J Biol Chem 274: 9108-9115, 1999. (Pubitemid 29164718)
21. Smahi A, Courtois G, Rabia SH, et al: The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 11: 2371-2375, 2002. (Pubitemid 35174700)
22. Fukuda M, Horiuchi Y, Oku Y, et al: Induction of apoptosis in human salivary gland tumor cells by anti-NCAM antibody. Oncol Rep 14: 1143-1149, 2005.
23. Ohmori Y and Hamilton TA: Interleukin-4/STAT6 represses STAT1 and NF-kappa B-dependent transcription through distinct mechanisms. J Biol Chem 275: 38095-38103, 2000. (Pubitemid 32004934)
24. Pindborg JJ, Reichart PA, Smith CJ and van der Waal I: Histological typing of cancer and precancer of the oral mucosa. World Health Organization International Histological Classification of tumors. 2nd edition, Springer-Verlag, Berlin, pp11-38, 1997.
25. Sobin LH and Wittekind CH (eds). UICC TNM classification of malignant tumors. 5th edition, John Wiley and Sons, Inc., New York, pp20-24, 2002.
26. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005. (Pubitemid 40568680)
27. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1-20, 2004.
28. + TH1-like responses. J Clin Invest 98: 1010-1020, 1996.
29. + regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65: 3998-4004, 2005.
30. Jäger E, Jäger D and Knuth A: Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106: 817-820, 2003.
31. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190: 705-715, 1999.
32. + T cells in patients with melanoma. J Immunol 175: 6169-6176, 2005.
33. Fukuda M, Tanaka A, Hamao A, Suzuki S, Kusama K and Sakashita H: Expression of RCAS1 and its function in human squamous cell carcinoma of the oral cavity. Oncol Rep 12: 259-267, 2004.
34. Shimozato O, Ugai S, Chiyo M, et al: The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117: 22-28, 2006.
35. Shan BE, Hao JS, Li QX and Tagawa M: Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol 3: 47-52, 2006.
36. Shan B, Yu L, Shimozato O, Li Q and Tagawa M: Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res 24: 79-82, 2004. (Pubitemid 38279691)
37. Lo CH, Lee SC, Wu PY, et al: Antitumor and antimetastatic activity of IL-23. J Immunol 171: 600-607, 2003.
38. Overwijk WW: Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol 17: 187-194, 2005. (Pubitemid 40343107)
39. Deveraux Q and Reed J: IAP family proteins: suppressors of apoptosis. Genes Dev 13: 239-252, 1999. (Pubitemid 29095796)